Nurela 50 mg (Capsule)
Unit Price: ৳ 12.00 (30's pack: ৳ 360.00)
Medicine Details
| Category | Details |
|---|---|
| Generic | Pregabalin |
| Company | Guardian healthcare ltd |
Indications
- Neuropathic pain associated with diabetic peripheral neuropathy (DPN)
- Postherpetic neuralgia (PHN)
- Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older
- Fibromyalgia
- Neuropathic pain associated with spinal cord injury
Pharmacology
- Structural derivative of gamma-aminobutyric acid (GABA)
- Binds to alpha2-delta site in CNS tissues
- Anti-nociceptive and antiseizure effects
Dosage
- Maximum recommended dose of 100 mg three times a day for DPN
- Recommended dose of 75 to 150 mg two times a day for PHN
- Recommended dose of 300 to 450 mg/day for fibromyalgia
- Recommended dose range of 150 to 600 mg/day for spinal cord injury
- Instructions for switching from Pregabalin capsules to Pregabalin CR capsule tablet
Administration
- Oral route of administration
- Can be taken with or without food
- Pregabalin CR tablet should be taken after an evening meal
- Instructions for missed doses and discontinuation
Interaction
- Unlikely involvement in significant pharmacokinetic drug interactions
- No interactions with food or others
Contraindications
- Contraindicated in patients with known hypersensitivity
Side Effects
- Dizziness
- Somnolence
- Dry mouth
- Edema
- Blurred vision
- Weight gain
- Difficulty with concentration/attention
Pregnancy & Lactation
- No adequate and well-controlled studies in pregnant women
- Small amounts detected in the milk of lactating women
- Breastfeeding not recommended due to potential risk of tumorigenicity
Precautions & Warnings
- Potential for angioedema
- Discontinue immediately in case of hypersensitivity reactions
- Increased risk of suicidal thoughts or behavior
- Monitor for respiratory depression
- May cause dizziness and somnolence
- Caution with concomitant use of CNS depressants
- Instructions for withdrawal
Use in Special Populations
- Safety and effectiveness not established in pediatric patients
- Safety and effectiveness not established in pediatric patients below 1 month
- Safety and effectiveness not established for Nurela extended-release tablet in pediatric patients
Overdose Effects
- Signs and symptoms include reduced consciousness, agitation, seizures
- No specific antidote
- General supportive care indicated
Therapeutic Class
- Adjunct anti-epileptic drugs
- Primary anti-epileptic drugs
Storage Conditions
- Keep in a cool & dry place (below 30°C)
- Protected from light & moisture
- Keep out of the reach of children
Chemical Structure
- Molecular Formula: C8H17NO2
- Image of chemical structure
Common Questions about Nurela 50 mg Capsule
- First-line treatment for neurotic pain, shingles, seizures, and fibromyalgia
- Frequency of use as prescribed by the doctor
- Store in a cool dry place and in original packaging
- Usage varies for different diseases
- Consult doctor before stopping